Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb�, GW572016) in an expanded panel of human normal and tumour cell lines-Reference-Cited by-同舟云学术

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb�, GW572016) in an expanded panel of human normal and tumour cell lines

Published:2007-08 Issue:4 Volume:40 Page:580-594
ISSN:0960-7722
Container-title:Cell Proliferation
language:en
Short-container-title:Cell Prolif

Author:

Rusnak D. W.,Alligood K. J.,Mullin R. J.,Spehar G. M.,Arenas-Elliott C.,Martin A.-M.,Degenhardt Y.,Rudolph S. K.,Jr Haws T. F.,Hudson-Curtis B. L.,Gilmer T. M.

Publisher

Wiley

Subject

Cell Biology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2184.2007.00455.x/fullpdf

Reference20 articles.

1. Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

2. FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets

3. United States Food and Drug Administration Drug Approval Summary

4. A small molecule–kinase interaction map for clinical kinase inhibitors

5. Clinical Implications of Human Papillomavirus in Head and Neck Cancers

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting EGFR by Newer 1-(3,5-Bis((E)-4‑hydroxy-3-methoxystyryl)-1H-pyrazol-1-yl)-2-((substituted phenyl)amino)ethan-1-one Analogues for the Treatment of Cancer: Synthesis, In-vitro and In-silico Studies;Journal of Molecular Structure;2024-11

2. Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review;Frontiers in Oncology;2024-08-22

3. Enhanced anti-tumor effects by combination of tucatinib and radiation in HER2-overexpressing human cancer cell lines;Cancer Cell International;2024-08-06

4. Enhanced Anti-Tumor Effects by Combination of Tucatinib and Radiation in HER2-Overexpressing Human Cancer Cell Lines;2024-04-09

5. Investigating new inhibitors with potential advantages for combating HER2-overexpressing head and neck squamous cancer cells; a practical and virtual screening study;2024-01-11